Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Ovid Therapeutics (OVID : NSDQ)

• Company Description    Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid Therapeutics Inc. is based in New York, United States. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $1.63 Daily Weekly Monthly 20 Day Moving Average: 1,396,505 shares Shares Outstanding: 71.21 (millions) Market Capitalization: $116.08 (millions) Beta: 0.22 52 Week High: $2.01 52 Week Low: $0.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.62% 0.79% 12 Week -6.32% -7.83% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 441 Ninth Avenue 14th Floor - New York,NY 10001 USA ph: 646-661-7661 fax: - investors@ovidrx.com http://www.ovidrx.com

• General Corporate Information    Officers Jeremy M. Levin - Chief Executive Officer and Director Jeffrey Rona - Chief Business and Financial Officer Karen Bernstein - Director Barbara Duncan - Director Bart Friedman - Director Peer Information Ovid Therapeutics (CORR.) Ovid Therapeutics (RSPI) Ovid Therapeutics (CGXP) Ovid Therapeutics (BGEN) Ovid Therapeutics (GTBP) Ovid Therapeutics (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 690469101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/10/26 Share - Related Items Shares Outstanding: 71.21 Most Recent Split Date: (:1) Beta: 0.22 Market Capitalization: $116.08 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.42 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.59 Price/Cash Flow: - Price / Sales: 17.56 EPS Growth vs. Year Ago Period: 15.00% vs. Previous Quarter: -183.33% Sales Growth vs. Year Ago Period: -23.70% vs. Previous Quarter: -97.90% ROE 12/31/25 - - 09/30/25 - -63.79 06/30/25 - -58.87 ROA 12/31/25 - - 09/30/25 - -46.15 06/30/25 - -43.18 Current Ratio 12/31/25 - - 09/30/25 - 4.24 06/30/25 - 4.72 Quick Ratio 12/31/25 - - 09/30/25 - 4.24 06/30/25 - 4.72 Operating Margin 12/31/25 - - 09/30/25 - -550.04 06/30/25 - -574.44 Net Margin 12/31/25 - - 09/30/25 - -550.04 06/30/25 - -574.44 Pre-Tax Margin 12/31/25 - - 09/30/25 - -549.64 06/30/25 - -574.03 Book Value 12/31/25 - - 09/30/25 - 0.63 06/30/25 - 0.78 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.28 06/30/25 - 0.23 Debt-to-Capital 12/31/25 - - 09/30/25 - 21.65 06/30/25 - 18.56

Powered by Zacks Investment Research ©